~ Frederick Douglass
Book your appointment now!By: Joann Amoroso-Pernice RDH, MAS™, QOM®
In a landmark move, the U.S. Food and Drug Administration (FDA) has approved Zepbound (tirzepatide) as the first-ever medication specifically for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults who also suffer from obesity. Manufactured by Eli Lilly, this approval marks a new era in OSA treatment, especially for patients who are unable to tolerate or adhere to traditional therapies like CPAP (Continuous Positive Airway Pressure). However, while this drug offers promising results, its side effects and potential risks mean that it may not be the right choice for everyone.... read more
Dec
By: CAFF Team
Are your children snoring, awakening with dry mouth and headaches, and having trouble staying awake and focused during the day?... read more
Oct
By: Joann Amoroso RDH , MAS, QOM
As we continue to explore and understand the full potential of new treatments, collaboration among healthcare providers remains crucial. By sharing knowledge and integrating various therapeutic approaches, we can offer our patients the best possible care and support.... read more
Jul